Biomerica, Inc.
BMRA · NASDAQ
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.47 | -0.56 | 2.35 |
| FCF Yield | -55.35% | -7.02% | -3.58% | -0.18% |
| EV / EBITDA | -1.07 | -12.46 | -21.32 | -88.93 |
| Quality | ||||
| ROIC | -112.60% | -86.93% | -56.81% | -46.97% |
| Gross Margin | 9.38% | 11.28% | 8.35% | 15.78% |
| Cash Conversion Ratio | 0.77 | 0.90 | 0.77 | 0.11 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.18% | -34.04% | -9.48% | 41.28% |
| Free Cash Flow Growth | 29.18% | 1.37% | -753.01% | 88.27% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | 0.56 | 1.26 | 1.15 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.23 | 2.02 | 2.38 | 6.58 |
| Cash Conversion Cycle | 140.86 | 222.48 | 177.07 | 53.55 |